Benefits cited include early recognition of infiltration, avoidance of serious injuries, and potential reduction in litigation
NEWPORT NEWS, Va., June 25, 2019 – A new study in the peer-reviewed Journal of the Association for Vascular Access (JAVA) examines several important metrics that describe the performance of the ivWatch Model 400 at a leading children’s hospital in Ohio. The key finding of the pilot study was the device detected a peripheral IV infiltration 80 percent of the time before the clinician detected the leakage event.
Data was collected on 156
patients where the ivWatch Model 400 was incorporated into IV therapy but did
not notify clinicians of infiltration, and then compared to data on 57 patients
where the ivWatch Model 400 notified clinicians via audible and visual alerts
about infiltration events. This allowed investigators to analyze how the ivWatch
Model 400 compared to clinicians’ assessments in the early detection of IV
infiltration. Success was measured by the frequency of infiltration events and
how often the device issued notifications.
The study, which appears in the
Summer 2019 issue of JAVA, showed that on average the device issued a
notification signaling a possible infiltration (Yellow Check IV) 32.3 hours
prior to a clinician detecting it, while a notification signaling a probable
infiltration (Red Check IV) was issued an average of 29.8 hours prior to
clinician detection. It was also concluded by the authors of the study at
Cincinnati Children’s Hospital, “technology that provides early detection of IV
infiltrations may be advantageous for the patient, clinician, and institution.”
This pilot study was undertaken in part because of the medical center’s commitment to patient safety including efforts to reduce severe and moderate peripheral IV infiltration and extravasation occurrences. The results underline the practice of using an additional intervention in conjunction with following industry recommendations of IV site assessment to promote the earliest possible identification of this common complication of IV therapy.
The study titled “The Use of
Optical Detection for Continuous Monitoring of Pediatric IV Sites” was authored
by Darcy Doellman, MSN, RN, CRNI, VA-BC and Sylvia Rineair, MSHA, BSN, RN,
VA-BC. The abstract can be viewed at https://www.avajournal.com/doi/abs/10.2309/j.java.2019.002.003, and the article citation is:
Darcy Doellman and Sylvia Rineair (2019) The Use of Optical Detection for Continuous Monitoring of Pediatric IV Sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.
About ivWatch: ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.
ivWatch is pleased
to sponsor the work of myIV.com, an
online resource dedicated to empowering visitors with information on all things
Patient Safety & Quality Healthcare (PSQH) discussed IV infiltration and it’s potential for life-threatening consequences in a recent article. The piece, “Companies Work to Help Combat IV Infiltrations” includes commentary from ivWatch President and CEO, Gary Warren, and cites the ivWatch Model 400 as a clinician partner helping to deliver improved patient care with constant monitoring of the IV site. Read the full article here.
Season 2 Episode 7 of the Association for Vascular Access ‘ISAVE That Podcast’ is sponsored by ivWatch. A myIV.com Patient Spotlight story about a severe pediatric infiltration injury was featured in an interview during the episode segment ‘Beyond the Manuscript.” Listen to the full episode here.
HAMPTON, Va., May 7, 2019 – ivWatch, a leading provider of biosensor technology focused on improving patient safety and the effectiveness of intravenous (IV) therapy, has entered into an exclusive distribution agreement with Roxon medi-tech, a distributor of specialized medical equipment based in Montreal, Quebec. The agreement includes the rights to distribute the ivWatch Model 400, the only device to receive clearance, globally, to offer early detection of infiltrations/extravasations, in the Canadian market.
“Many health systems and children’s hospitals
in Canada have recognized peripheral IV infiltration as a serious safety event,”
said Scott Hensley, executive vice president of sales and business development
at ivWatch. “Providing access to ivWatch technology in collaboration with Roxon
strengthens our international reach, which continues to be a core priority for
Every infiltration is a medication
dosing and delivery error that can impact the patient through prolonged
hospital stays, temporary harm or permanent injuries. The team at Roxon intends
to leverage their long-standing industry networks to educate on the prevalence
of IV failures and the importance of surveillance monitoring to improve patient
“We’re ready to expand on the
market excitement as we usher the ivWatch breakthrough technology movement to
our large network of Canadian clinicians,” said Roxon President Michael
Solomita. “Our deep market expertise combined with adding this innovative product
to our portfolio complements our mission of providing the safest medical
devices with the highest industry standards to patients throughout the country.”
ivWatch has previously announced the
issuance of a medical device license (MDL) by Health Canada permitting the
company to sell the ivWatch
Model 400 to Canadian health care
organizations, as well as achieving ISO 13485 Certification, the global standard for medical
device quality management systems (QMS) developed by the International
Organization for Standardization (ISO®).
than a billion IV catheters sold globally every year, the drug delivery errors
caused by IV infiltration and extravasation urgently needs to be addressed,” said
Gary Warren, president and CEO of ivWatch. “Delivering ivWatch technology to
health care systems outside the U.S. that are actively looking for a solution is
crucial for addressing this huge unmet need in vascular access. Working with
our distribution partners, we can reach more patients and assist institutions worldwide
with keeping patients safe from preventable harm.”
About ivWatch: ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.
is pleased to sponsor the work of myIV.com, an online resource dedicated to
empowering visitors with information on all things IV, simplified.
MEDIA CONTACT: Amara Betoney, email@example.com, Direct (757)
224-2606, Office (855) 489-2824 x7007, Mobile (757) 660-4949
ivWatch President and CEO Discusses Improving Quality of Care
ivWatch President and CEO Gary Warren was interviewed for the series “Future of Healthcare,” to analyze what improvements must be made to deliver better care at a lower cost. Warren reviews his own patient journey and how the ivWatch company mission became personal. The questions posed are responded to with an overview of the challenges when creating a market for a new medical technology, and the rewards of extending the ivWatch technology to more patients by starting a patient safety movement within hospital walls.
He closes with how improving drug efficacy is a matter of life and death for the critically ill or injured patient. Read the full Medium/Authority Magazine interview here.
Virginia Business Magazine Features ivWatch in May 2019 Issue
ivWatch President and CEO, Gary Warren, shares his perspective on what it takes develop a startup into a category-leading medical device manufacturer and biosensor technology company. In the VirginiaBusiness.com article, “Interview with an Innovator,” Warren describes high expectations and medical device design standards, as well as ivWatch’s relentless pursuit of solving an unmet need in health care. The interview, also in the May 2019 print issue, is available here.
Placing IV pumps outside to save PPE? Who is monitoring your patient's IV site? ivWatch provides continuous IV site monitoring for infiltration and extravasation even while you are not in the room.Learn More
Download Our Whitepaper
Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.